PMID- 34660744
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220317
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 8
DP  - 2021
TI  - Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for 
      Intervention.
PG  - 746382
LID - 10.3389/fcvm.2021.746382 [doi]
LID - 746382
AB  - Heart failure is an important manifestation of diabetic heart disease. Before the 
      development of symptomatic heart failure, as much as 50% of patients with type 2 
      diabetes mellitus (T2DM) develop asymptomatic left ventricular dysfunction 
      including left ventricular hypertrophy (LVH). Left ventricular hypertrophy (LVH) 
      is highly prevalent in patients with T2DM and is a strong predictor of adverse 
      cardiovascular outcomes including heart failure. Importantly regression of LVH 
      with antihypertensive treatment especially renin angiotensin system blockers 
      reduces cardiovascular morbidity and mortality. However, this approach is only 
      partially effective since LVH persists in 20% of patients with hypertension who 
      attain target blood pressure, implicating the role of other potential mechanisms 
      in the development of LVH. Moreover, the pathophysiology of LVH in T2DM remains 
      unclear and is not fully explained by the hyperglycemia-associated cellular 
      alterations. There is a growing body of evidence that supports the role of 
      inflammation, oxidative stress, AMP-activated kinase (AMPK) and insulin 
      resistance in mediating the development of LVH. The recognition of asymptomatic 
      LVH may offer an opportune target for intervention with cardio-protective therapy 
      in these at-risk patients. In this article, we provide a review of some of the 
      key clinical studies that evaluated the effects of allopurinol, SGLT2 inhibitor 
      and metformin in regressing LVH in patients with and without T2DM.
CI  - Copyright (c) 2021 Mohan, Dihoum, Mordi, Choy, Rena and Lang.
FAU - Mohan, Mohapradeep
AU  - Mohan M
AD  - Division of Mental Health and Wellbeing, Warwick Medical School, University of 
      Warwick, Coventry, United Kingdom.
AD  - Division of Molecular and Clinical Medicine, School of Medicine, Ninewells 
      Hospital and Medical School, University of Dundee, Dundee, United Kingdom.
FAU - Dihoum, Adel
AU  - Dihoum A
AD  - Division of Molecular and Clinical Medicine, School of Medicine, Ninewells 
      Hospital and Medical School, University of Dundee, Dundee, United Kingdom.
FAU - Mordi, Ify R
AU  - Mordi IR
AD  - Division of Molecular and Clinical Medicine, School of Medicine, Ninewells 
      Hospital and Medical School, University of Dundee, Dundee, United Kingdom.
FAU - Choy, Anna-Maria
AU  - Choy AM
AD  - Division of Molecular and Clinical Medicine, School of Medicine, Ninewells 
      Hospital and Medical School, University of Dundee, Dundee, United Kingdom.
FAU - Rena, Graham
AU  - Rena G
AD  - Division of Molecular and Clinical Medicine, School of Medicine, Ninewells 
      Hospital and Medical School, University of Dundee, Dundee, United Kingdom.
FAU - Lang, Chim C
AU  - Lang CC
AD  - Division of Molecular and Clinical Medicine, School of Medicine, Ninewells 
      Hospital and Medical School, University of Dundee, Dundee, United Kingdom.
AD  - UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia, 
      Kuala Lumpur, Malaysia.
LA  - eng
GR  - PG/14/4/30539/BHF_/British Heart Foundation/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20210929
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC8513785
OTO - NOTNLM
OT  - SGLT2 inhibitors
OT  - allopurinol
OT  - diabetic cardiomyopathy (DCM)
OT  - heart failure
OT  - left ventricular hypertrophy (LVH)
OT  - metformin
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/10/19 06:00
MHDA- 2021/10/19 06:01
PMCR- 2021/01/01
CRDT- 2021/10/18 09:09
PHST- 2021/07/23 00:00 [received]
PHST- 2021/09/02 00:00 [accepted]
PHST- 2021/10/18 09:09 [entrez]
PHST- 2021/10/19 06:00 [pubmed]
PHST- 2021/10/19 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2021.746382 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2021 Sep 29;8:746382. doi: 10.3389/fcvm.2021.746382. 
      eCollection 2021.